Researchers in Chicago presented new data Monday that has big implications for lung cancer patients. A clinical trial discovered that pairing immunotherapy drugs with standard chemotherapy could significantly increase survival rates in lung cancer patients, Stat reports.
A trial study called Keynote-189 found that newly diagnosed lung cancer patients were 51 percent more likely to be alive in a year if they underwent a regimen that combined Keytruda, an immunotherapy drug by the pharmaceutical company Merck, with standard chemotherapy, than if they received chemotherapy treatment alone. Patients with the combined treatment were also 48 percent less likely to have their cancer progress in that year.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstancesSpeed Read
-
Western mountain climbers allegedly left Pakistani porter to die on K2Speed Read
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governorSpeed Read
-
Los Angeles city workers stage 1-day walkout over labor conditionsSpeed Read
-
Mega Millions jackpot climbs to an estimated $1.55 billionSpeed Read
-
Bangladesh dealing with worst dengue fever outbreak on recordSpeed Read
-
Glacial outburst flooding in Juneau destroys homesSpeed Read
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creatureSpeed Read
